1st Quarter - Report — STARBUCKS CORPORATION for STARBUCKS CORPORATION (2012)

Firm

STARBUCKS CORPORATION

Client

STARBUCKS CORPORATION

Income

—

Expenses

$160,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Transportation TRA

Issues regarding S. Amendment 1742 to S. 1813 (entire amendment).

Lobbyist	Covered position, as disclosed
LORI OTTO PUNKE	—

Contacted: Food & Drug Administration (FDA); White House Office; Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1813 (112th)

Banking BAN

Public Law 111-203 - Dodd-Frank Wall Street Reform and Consumer Protection Act; financial reform related to interchange(no specific bill).

Lobbyist	Covered position, as disclosed
LORI OTTO PUNKE	—

Contacted: Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office

Taxation/Internal Revenue Code TAX

Tax proposals regarding the treatment of foreign income, including advocating for a proposal to expand the active royalties exception (no specific bill number).

Lobbyist	Covered position, as disclosed
LORI OTTO PUNKE	—

Contacted: Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Health care and health care technology issues including A) Implementation of PL 111-148 - Patent Protection and Affordable Care Act (PPACA); B) implementation of menu labeling requirements; and C) development of health information technologies and their relationship to self-funded health benefit plans (no specific bill number).

Lobbyist	Covered position, as disclosed
LORI OTTO PUNKE	—

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Food Industry (safety, labeling, etc.) FOO

PL 111-148 - Patent Protection and Affordable Care Act (PPACA) with respect to implementation of menu labeling requirements. Issues relating to FDA sodium reduction efforts (no specific bill). Discuss possible partnership opportunities regarding health and wellness initiatives (no specific bill).

Lobbyist	Covered position, as disclosed
LORI OTTO PUNKE	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.